ImmuPharma's H1 financials boosted by Lupuzor progress
This article was originally published in Scrip
Executive Summary
ImmuPharma has reported revenues of £21.6 million and net profit of £11.7 million in the first half of 2009, up from £97,000 and a net loss of £1.5 million respectively in the same period last year. The company's cash and cash equivalents rose from £12.5 million at the end of December 2008 to £27.1 million on June 30th, 2009.